Docoh
Loading...

CSTL Castle Biosciences

News

From Benzinga Pro
Cathie Wood's ARK Invest Posts Fund Sales For Tuesday, Nov. 30, 2021: Z, PRLB, TSLA, COIN, U, FTCH, CDXS, CSTL, INCY, IOVA, REGN, PINS
1 Dec 21
Hedge Funds, Trading Ideas, General
ZILLOW GROUP INC (Z) - 10231 PROTO LABS INC (PRLB) - 4749 TESLA INC (TSLA) - 30034 COINBASE GLOBAL INC (COIN) - 158437 UNITY SOFTWARE INC (U) - 325987 FARFETCH LTD (FTCH) - 11744 CODEXIS INC (CDXS) -
Castle Biosciences Highlights Data On DecisionsDx-Melanoma Published In 'Future Oncology'
19 Nov 21
Biotech, News, FDA, General
Data demonstrated that patients with a DecisionDx-Melanoma Class 1A (low risk) test result had a five-year recurrence-free survival rate and distant metastasis-free survival rate of 95.8% and 99.2%,
Cathie Wood's ARK Invest Posts Fund Sales For Tuesday, Nov. 9, 2021: PRLB, U, RBLX, CSTL, CLLS, REGN, PFE
10 Nov 21
Hedge Funds, Trading Ideas, General
Proto Labs (PRLB) Unity Software (U) Roblox (RBLX) Castle Biosciences (CSTL) Cellectis (CLLS) Regeneron Pharmaceuticals (REGN) Pfizer (PFE)
SVB Leerink Maintains Outperform on Castle Biosciences, Lowers Price Target to $75
9 Nov 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Puneet Souda maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and lowers the price target from $85 to $75.
Cathie Wood's ARK Invest Posts Fund Sales For Monday, Nov. 8, 2021: PRLB, COIN, U, CSTL, CLLS
9 Nov 21
Hedge Funds, Trading Ideas, General
Proto Labs (PRLB) Coinbase Global (COIN) Unity Software (U) Castle Biosciences (CSTL) Cellectis (CLLS)
Castle Biosciences Q3 EPS $(0.47) Misses $(0.40) Estimate, Sales $23.48M Beat $22.97M Estimate
8 Nov 21
Earnings, News
Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.40) by 17.5 percent. This is a 104.35 percent decrease over losses of $(0.23) per share
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Nov. 5, 2021: PRLB, NSTG, Z, PYPL, IOVA, CSTL, REGN, PINS, NVDA
8 Nov 21
Hedge Funds, Trading Ideas, General
Proto Labs (PRLB) NanoString Technologies (NSTG) Zillow Group (Z) PayPal Holdings (PYPL) Iovance Biotherapeutics (IOVA) Castle Biosciences (CSTL) Regeneron Pharmaceuticals (REGN) Pinterest
Earnings Scheduled For November 8, 2021
8 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Cathie Wood's ARK Invest Posts Fund Sales For Thursday, Nov. 4, 2021
5 Nov 21
Hedge Funds, Trading Ideas, General
Proto Labs (PRLB) Tesla (TSLA) Zillow (Z, ZG) Unity Software (U) Lockheed Martin (LMT) Castle Biosciences (CSTL) Iovance Biotherapeutics (IOVA) Opendoor Technologies (OPEN)
Cathie Wood's ARK Invest Posts Fund Sales For Wednesday, Nov. 3, 2021
4 Nov 21
Hedge Funds, Trading Ideas, General
Proto Labs (PRLB) Tesla (TSLA) Zillow (Z, ZG) Lockheed Martim (LMT) Unity Software (U) Castle Biosciences (CSTL) Iovance Biotherapeutics (IOVA) Regeneron (REGN)
Cathie Wood's ARK Invest Posts Fund Sales For Tues, Nov. 2, 2021: TSLA, LMT, PLTR, U, CSTL, IOVA, NSTG, PINS
3 Nov 21
Hedge Funds, Trading Ideas, General
Tesla (TSLA) - 80,100 Lockheed Martin (LMT) - 7,700 Palantir Technologies (PLTR) - 847,901 Unity Software (U) - 178310 Castle Biosciences (CSTL) - 8,174 Iovance
Cathie Wood's ARK Invest Posts Fund Sales For Monday, Nov. 1, 2021: LMT, U, PYPL, TAK, CSTL, IOVA, TXG, NSTG, VEEV, PLTR, PINS, NVDA
2 Nov 21
Hedge Funds, Trading Ideas, General
Lockheed Martin (LMT) - 10,400 Unity Software (U) - 90,958 PayPal Holdings (PYPL) - 1,855 Takeda Pharmaceutical (TAK) - 101,857 Castle Biosciences (CSTL)
Castle Biosciences Highlights New Data Further Validating Performance Of Co.'s DecisionDx DiffDx -Melanoma Test
26 Oct 21
Biotech, News, FDA, General
Presentation highlights data from second independent study validating DecisionDx® DiffDx™-Melanoma as an ancillary melanoma diagnostic tool for difficult-to-diagnose melanocytic lesions FRIENDSWOOD,
Castle Biosciences Reports Will Be Acquired By Pittsburgh Life Science Greenhouse, No Terms Disclosed
25 Oct 21
M&A
Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cernostics, Inc., is being acquired by Castle Biosciences (NASDAQ:CSTL). Cernostics specializes in spatial
Cathie Wood's ARK Invest Posts Fund Sales For Thursday, Sept. 30, 2021: SKLZ, PRLB, TER, NSTG, NTDOY, SE, NXPI, LC, SNAP, ETSY, BMY, CLLS, CRBU, CDXS, NVS, SMFR, CSTL, SDGR
1 Oct 21
Hedge Funds, Trading Ideas, General
Skillz (SKLZ) - 15,704 Shares Proto Labs (PRLB) - 7,407 Teradyne (TER) - 16,083 NanoString Technologies (NSTG) - 133,767 Nintendo (NTDOY) - 254,687 Sea (SE) - 80,800 NXP Semiconductors (NXPI) -
Cathie Wood's ARK Invest Posts Fund Sales For Monday, Sept. 27, 2021: TER, SNPS, TSLA, TWLO, SMFR, CDXS, CLLS, CSTL, CRBU, NVS, MELI, SE, HEI
28 Sep 21
Hedge Funds, Trading Ideas, General
Teradyne (TER) - 67,000 Synopsys (SNPS) - 25,099 Tesla (TSLA) - 24,361 Twilio (TWLO) - 31,431 Sema4 Holdings (SMFR) - 1,200 Codexis (CDXS) - 1,200 Cellectis
Castle Biosciences's Return On Capital Employed Overview
16 Sep 21
Earnings
Castle Biosciences (NASDAQ:CSTL) brought in sales totaling $22.76 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 105.65%, resulting in a loss of $8.81 million.

Press releases

From Benzinga Pro
Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio
24 Nov 21
Press Releases
Presented at American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting Castle Biosciences, Inc. (NASDAQ:CSTL), a company applying innovative diagnostics to inform disease management decisions and improve
Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology
19 Nov 21
Press Releases
Data demonstrated that patients with a DecisionDx-Melanoma Class 1A (low risk) test result had a five-year recurrence-free survival rate and distant metastasis-free survival rate of 95.8% and 99.2%, respectively Castle
Castle Biosciences Named in Inc.'s First-Annual Best-Led Companies
17 Nov 21
Press Releases
Inaugural roundup of companies includes top 250 that proved management excellence across the middle market Castle Biosciences, Inc. (NASDAQ:CSTL), a company applying innovative diagnostics to transform disease
Castle Biosciences Named a 2021 Houston Chronicle Top Workplace
15 Nov 21
Press Releases
Castle Biosciences, Inc. (NASDAQ:CSTL), a company applying innovative diagnostics to transform disease management and improve patient outcomes, today announced that the Company has been named a 2021 Houston Chronicle
Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
10 Nov 21
Press Releases
Castle Biosciences, Inc. (NASDAQ:CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, today announced that Derek Maetzold, president and chief executive
Castle Biosciences Announces Third Quarter 2021 Results
8 Nov 21
Press Releases
Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million Q3 2021 total dermatology test report volume of 7,352 On track to achieve 2021 total revenue guidance of $89-93 million Conference call and
Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm
5 Nov 21
Press Releases
Study demonstrated improved prediction for sentinel lymph node (SLN) status compared to clinicopathologic features alone Study also demonstrated that DecisionDx®-Melanoma's i31-GEP SLNB algorithm provides high
Castle Biosciences' Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System
4 Nov 21
Press Releases
Interface facilitates ease of ordering within the dermatologic EMR platform Castle Biosciences, Inc. (NASDAQ:CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient
DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence
28 Oct 21
Press Releases
i31-GEP for Risk of Recurrence algorithm integrates DecisionDx-Melanoma score with clinicopathologic factors to provide patient-specific five-year outcomes Castle Biosciences, Inc. (NASDAQ:CSTL), a company applying
Pittsburgh Life Sciences Greenhouse Proudly Announces Portfolio Company Cernostics is Being Acquired by Castle Biosciences
25 Oct 21
Press Releases
PITTSBURGH, Oct. 25, 2021 /PRNewswire/ -- Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cernostics, Inc., is being acquired by Castle Biosciences
Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021
25 Oct 21
Press Releases
Castle Biosciences, Inc. (NASDAQ:CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, today announced that it will release its financial results for the
Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021
22 Oct 21
Press Releases
The Company also highlights the study design for its pipeline program to predict response to systemic therapeutics in patients diagnosed with moderate to severe inflammatory dermatologic conditions Castle Biosciences,
Castle Biosciences Announces New York Approval of DecisionDx® DiffDx™-Melanoma
16 Sep 21
Press Releases
Castle Biosciences, Inc. (NASDAQ:CSTL), a dermatologic diagnostics company providing personalized genomic information to improve treatment decisions, today announced that it has received approval from the New York State